Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Differentiation Between Pediatric Irritable Bowel Syndrome and Inflammatory Bowel Disease Based on Fecal Scent: Proof of Principle Study.

Bosch S, van Gaal N, Zuurbier RP, Covington JA, Wicaksono AN, Biezeveld MH, Benninga MA, Mulder CJ, de Boer NKH, de Meij TGJ.

Inflamm Bowel Dis. 2018 Oct 12;24(11):2468-2475. doi: 10.1093/ibd/izy151.

PMID:
29788410
2.

Faecal volatile organic compounds analysis using field asymmetric ion mobility spectrometry: non-invasive diagnostics in paediatric inflammatory bowel disease.

van Gaal N, Lakenman R, Covington J, Savage R, de Groot E, Bomers M, Benninga M, Mulder C, de Boer N, de Meij T.

J Breath Res. 2017 Nov 29;12(1):016006. doi: 10.1088/1752-7163/aa6f1d.

PMID:
28439048
3.

Optimized Sampling Conditions for Fecal Volatile Organic Compound Analysis by Means of Field Asymmetric Ion Mobility Spectrometry.

Bosch S, El Manouni El Hassani S, Covington JA, Wicaksono AN, Bomers MK, Benninga MA, Mulder CJJ, de Boer NKH, de Meij TGJ.

Anal Chem. 2018 Jul 3;90(13):7972-7981. doi: 10.1021/acs.analchem.8b00688. Epub 2018 Jun 15.

4.

An investigation of fecal volatile organic metabolites in irritable bowel syndrome.

Ahmed I, Greenwood R, Costello Bde L, Ratcliffe NM, Probert CS.

PLoS One. 2013;8(3):e58204. doi: 10.1371/journal.pone.0058204. Epub 2013 Mar 13.

5.

Fecal Amino Acid Analysis Can Discriminate De Novo Treatment-Naïve Pediatric Inflammatory Bowel Disease From Controls.

Bosch S, Struys EA, van Gaal N, Bakkali A, Jansen EW, Diederen K, Benninga MA, Mulder CJ, de Boer NKH, de Meij TGJ.

J Pediatr Gastroenterol Nutr. 2018 May;66(5):773-778. doi: 10.1097/MPG.0000000000001812.

PMID:
29112087
6.

Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.

Chang MH, Chou JW, Chen SM, Tsai MC, Sun YS, Lin CC, Lin CP.

Mol Med Rep. 2014 Jul;10(1):522-6. doi: 10.3892/mmr.2014.2180. Epub 2014 Apr 24.

PMID:
24788223
7.

Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome.

Däbritz J, Musci J, Foell D.

World J Gastroenterol. 2014 Jan 14;20(2):363-75. doi: 10.3748/wjg.v20.i2.363. Review.

8.

A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS.

Menees SB, Powell C, Kurlander J, Goel A, Chey WD.

Am J Gastroenterol. 2015 Mar;110(3):444-54. doi: 10.1038/ajg.2015.6. Epub 2015 Mar 3. Review.

PMID:
25732419
9.

Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome.

Silberer H, Küppers B, Mickisch O, Baniewicz W, Drescher M, Traber L, Kempf A, Schmidt-Gayk H.

Clin Lab. 2005;51(3-4):117-26.

PMID:
15819166
10.

Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation.

Chung-Faye G, Hayee B, Maestranzi S, Donaldson N, Forgacs I, Sherwood R.

Inflamm Bowel Dis. 2007 Nov;13(11):1374-8.

PMID:
17577247
11.

Accuracy of four fecal assays in the diagnosis of colitis.

Schoepfer AM, Trummler M, Seeholzer P, Criblez DH, Seibold F.

Dis Colon Rectum. 2007 Oct;50(10):1697-706.

PMID:
17762964
12.

Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.

Kaiser T, Langhorst J, Wittkowski H, Becker K, Friedrich AW, Rueffer A, Dobos GJ, Roth J, Foell D.

Gut. 2007 Dec;56(12):1706-13. Epub 2007 Aug 3.

13.

Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders.

Caviglia GP, Pantaleoni S, Touscoz GA, Adriani A, Rosso C, Smedile A, Pellicano R, Astegiano M, Bresso F.

Scand J Gastroenterol. 2014 Dec;49(12):1419-24. doi: 10.3109/00365521.2014.934913. Epub 2014 Nov 5.

14.

Fecal lactoferrin in discriminating inflammatory bowel disease from irritable bowel syndrome: a diagnostic meta-analysis.

Zhou XL, Xu W, Tang XX, Luo LS, Tu JF, Zhang CJ, Xu X, Wu QD, Pan WS.

BMC Gastroenterol. 2014 Jul 7;14:121. doi: 10.1186/1471-230X-14-121. Review.

15.

Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies.

Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmid B, Seibold F.

Inflamm Bowel Dis. 2008 Jan;14(1):32-9.

PMID:
17924558
16.

Semiquantitative fecal calprotectin test in postinfectious and non-postinfectious irritable bowel syndrome: cross-sectional study.

David LE, Surdea-Blaga T, Dumitrascu DL.

Sao Paulo Med J. 2015 Jul-Aug;133(4):343-9. doi: 10.1590/1516-3180.2014.8000815. Epub 2014 Dec 19.

17.

Fecal volatile organic compounds: a novel, cheaper method of diagnosing inflammatory bowel disease?

Probert CS, Reade S, Ahmed I.

Expert Rev Clin Immunol. 2014 Sep;10(9):1129-31. doi: 10.1586/1744666X.2014.943664. Epub 2014 Jul 28.

PMID:
25066268
18.

Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.

Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ.

Am J Gastroenterol. 2008 Jan;103(1):162-9. Epub 2007 Oct 4.

PMID:
17916108
19.

The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission.

Hoekman DR, Zeevenhooven J, D'Haens GR, Benninga MA.

Eur J Gastroenterol Hepatol. 2017 Sep;29(9):1086-1090. doi: 10.1097/MEG.0000000000000921.

PMID:
28639969
20.

Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Kandala NB, Shyangdan D, Arasaradnam R, Clar C, Johnston R.

Health Technol Assess. 2013 Nov;17(55):xv-xix, 1-211. doi: 10.3310/hta17550. Review.

Supplemental Content

Support Center